These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 24291820)

  • 1. Stability engineering of the human antibody repertoire.
    Rouet R; Lowe D; Christ D
    FEBS Lett; 2014 Jan; 588(2):269-77. PubMed ID: 24291820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward aggregation-resistant antibodies by design.
    Lee CC; Perchiacca JM; Tessier PM
    Trends Biotechnol; 2013 Nov; 31(11):612-20. PubMed ID: 23932102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of humanized antibodies: from anti-Tac to Zenapax.
    Tsurushita N; Hinton PR; Kumar S
    Methods; 2005 May; 36(1):69-83. PubMed ID: 15848076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
    Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
    Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based engineering of a monoclonal antibody for improved solubility.
    Wu SJ; Luo J; O'Neil KT; Kang J; Lacy ER; Canziani G; Baker A; Huang M; Tang QM; Raju TS; Jacobs SA; Teplyakov A; Gilliland GL; Feng Y
    Protein Eng Des Sel; 2010 Aug; 23(8):643-51. PubMed ID: 20543007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering aggregation-resistant antibodies.
    Perchiacca JM; Tessier PM
    Annu Rev Chem Biomol Eng; 2012; 3():263-86. PubMed ID: 22468604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering fully human monoclonal antibodies from murine variable regions.
    Bernett MJ; Karki S; Moore GL; Leung IW; Chen H; Pong E; Nguyen DH; Jacinto J; Zalevsky J; Muchhal US; Desjarlais JR; Lazar GA
    J Mol Biol; 2010 Mar; 396(5):1474-90. PubMed ID: 20045416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resolving self-association of a therapeutic antibody by formulation optimization and molecular approaches.
    Casaz P; Boucher E; Wollacott R; Pierce BG; Rivera R; Sedic M; Ozturk S; Thomas WD; Wang Y
    MAbs; 2014; 6(6):1533-9. PubMed ID: 25484044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection, design, and engineering of therapeutic antibodies.
    Presta LG
    J Allergy Clin Immunol; 2005 Oct; 116(4):731-6; quiz 737. PubMed ID: 16210043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in Antibody Design.
    Tiller KE; Tessier PM
    Annu Rev Biomed Eng; 2015; 17():191-216. PubMed ID: 26274600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering antibodies by yeast display.
    Boder ET; Raeeszadeh-Sarmazdeh M; Price JV
    Arch Biochem Biophys; 2012 Oct; 526(2):99-106. PubMed ID: 22450168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggregation, stability, and formulation of human antibody therapeutics.
    Lowe D; Dudgeon K; Rouet R; Schofield P; Jermutus L; Christ D
    Adv Protein Chem Struct Biol; 2011; 84():41-61. PubMed ID: 21846562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction and Reduction of the Aggregation of Monoclonal Antibodies.
    van der Kant R; Karow-Zwick AR; Van Durme J; Blech M; Gallardo R; Seeliger D; Aßfalg K; Baatsen P; Compernolle G; Gils A; Studts JM; Schulz P; Garidel P; Schymkowitz J; Rousseau F
    J Mol Biol; 2017 Apr; 429(8):1244-1261. PubMed ID: 28322916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boosting antibody developability through rational sequence optimization.
    Seeliger D; Schulz P; Litzenburger T; Spitz J; Hoerer S; Blech M; Enenkel B; Studts JM; Garidel P; Karow AR
    MAbs; 2015; 7(3):505-15. PubMed ID: 25759214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and application of antibody cysteine variants.
    Voynov V; Chennamsetty N; Kayser V; Wallny HJ; Helk B; Trout BL
    Bioconjug Chem; 2010 Feb; 21(2):385-92. PubMed ID: 20092294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody therapeutics, antibody engineering, and the merits of protein stability.
    Demarest SJ; Glaser SM
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SDR grafting--a new approach to antibody humanization.
    Kashmiri SV; De Pascalis R; Gonzales NR; Schlom J
    Methods; 2005 May; 36(1):25-34. PubMed ID: 15848072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and molecular characterization of mouse single-chain variable fragment antibodies against Burkholderia mallei and Burkholderia pseudomallei.
    Kim HS; Tsai S; Zou N; Lo SC; Wear DJ; Izadjoo MJ
    J Immunol Methods; 2011 Feb; 365(1-2):101-9. PubMed ID: 21172353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody engineering and modification technologies.
    Filpula D
    Biomol Eng; 2007 Jun; 24(2):201-15. PubMed ID: 17466589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.